Numerous coronavirus vaccine development programmes are currently being run at a fast pace, with some promising candidates. That said, there is a strong possibility that when closer to licensing and approval, the manufacturing capacity won't be enough to deliver a global vaccination programme that would meet the principle of universal access, equity and prioritization of supply to benefit the most vulnerable populations
It is possible that this dilemma will be further exacerbated by the type of public funding arrangements that have been put in place to support vaccine developers in their research and development efforts. Such funding usually comes with obligations for the manufacturers to produce on the territory of the country providing financial resources, which may in turn result in restriction of exports, and limited availability of the vaccine beyond the population of the countries in question.
The Developing Countries Vaccine Manufacturers Network (DCVMN) accounts for the majority of vaccines produced at more than 65% in each WHO region except the European Region (EUR). This network of 40 manufacturers, located in developing countries such as India, Indonesia, South Korea, Brazil, China, South Africa, needs to be put to work.
The World Economic Forum proposes creating a pairing mechanism for vaccine innovators and vaccine manufacturers. It aims to protect both innovators, who will find capacity to produce, and manufacturers, who will access vaccine candidates at the right clinical development pathways – i.e. when they reach phase 3 and no earlier, hence averting the need for innovators to unilaterally and exclusively secure large capacities from individual manufacturers while their vaccines are yet unproven.
A mechanism like the one described in the above would represent a departure from the way traditional market forces are traditionally shaping the vaccine manufacturing landscape, by encouraging bilateral agreements between vaccine researchers and manufacturers. The Great Reset requires those types of mechanisms where the interest of all prevail over the ones of an elite. In the words of President Macron: “A vaccine is a global public good, which is not submitted to market forces."
• Current manufacturing capacity may not be enough to supply a global COVID-19 vaccination programme, therefore, more partnerships between researchers and manufacturers are needed.
• One solution requires hacking the current system.
• A pairing mechanism for vaccine innovators and vaccine manufacturers would protect innovators, who will find capacity to produce, and manufacturers, who will access vaccine candidates at the right clinical development pathways.
• This represents a departure from the way traditional market forces shape the vaccine manufacturing landscape, but a vaccine is a global public good, not something to profit from.
Not a Subscriber?
Receive Exchange Magazine Business Monitor by email.